Abdelmoemen Ghada, Khodeir Samy Abdelkader, Zaki Ahmed Nabil, Kassab Maha, Abou-Saif Sabry, Abd-Elsalam Sherief
Department of Clinical Pathology, Faculty of Medicine, Tanta University, Egypt.
Department of Internal Medicine, Faculty of Medicine, Tanta University, Egypt.
Endocr Metab Immune Disord Drug Targets. 2019;19(2):185-188. doi: 10.2174/1871530318666180716100543.
BACKGROUND & AIMS: Insulin resistance is the real determinant of both Nonalcoholic fatty liver disease (NAFLD) and diabetes, and can facilitate the accumulation of triglycerides in the liver. Overexpression of hepassocin (HPS) increased the accumulation of hepatic fat and NAFLD activity scores (NAS) in mice. The aim of this study was to investigate the relationship between hepassocin and steatosis of the liver in diabetic patients with or without NAFLD in humans.
The study enrolled 60 patients plus 20 healthy controls that were divided into 4 groups: Group I: included 20 patients who were diagnosed as diabetes mellitus type 2, Group II: included 20 patients who were diagnosed as nonalcoholic fatty liver disease (NAFLD), Group III: included 20 patients who were diagnosed as diabetes type 2 and NAFLD, and Group IV (control group): included 20 healthy person or controls who were matched in age and sex with patients group. All patients and controls were subjected to full history taking, thorough clinical examination, laboratory investigations including measurement of serum hepassocin in peripheral blood by ELISA technique.
There was a significant overexpression of serum hepassocin in patients with type 2 diabetes and NAFLD patients (Group 3) more than diabetic patients (Group 1) and even more than non-alcoholic fatty liver disease (Group 2).
This study provides evidence that increased HPS may facilitate increased hepatic lipid accumulation with NAFLD and type 2 diabetes.
胰岛素抵抗是非酒精性脂肪性肝病(NAFLD)和糖尿病的真正决定因素,并且可促进肝脏中甘油三酯的积累。肝辛蛋白(HPS)的过表达增加了小鼠肝脏脂肪的积累和NAFLD活动评分(NAS)。本研究的目的是调查肝辛蛋白与人类患有或未患有NAFLD的糖尿病患者肝脏脂肪变性之间的关系。
该研究招募了60名患者以及20名健康对照者,将其分为4组:第一组:包括20名被诊断为2型糖尿病的患者;第二组:包括20名被诊断为非酒精性脂肪性肝病(NAFLD)的患者;第三组:包括20名被诊断为2型糖尿病和NAFLD的患者;第四组(对照组):包括20名年龄和性别与患者组相匹配的健康人或对照者。所有患者和对照者均进行了全面的病史采集、彻底的临床检查、实验室检查,包括通过ELISA技术测量外周血中的血清肝辛蛋白。
2型糖尿病患者和NAFLD患者(第三组)血清肝辛蛋白的过表达明显高于糖尿病患者(第一组),甚至高于非酒精性脂肪性肝病患者(第二组)。
本研究提供了证据,表明HPS增加可能会促进NAFLD和2型糖尿病患者肝脏脂质积累增加。